These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23167815)

  • 81. New Aspects of Kidney Fibrosis-From Mechanisms of Injury to Modulation of Disease.
    Moeller MJ; Kramann R; Lammers T; Hoppe B; Latz E; Ludwig-Portugall I; Boor P; Floege J; Kurts C; Weiskirchen R; Ostendorf T
    Front Med (Lausanne); 2021; 8():814497. PubMed ID: 35096904
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The genetics of kidney stone disease and nephrocalcinosis.
    Singh P; Harris PC; Sas DJ; Lieske JC
    Nat Rev Nephrol; 2022 Apr; 18(4):224-240. PubMed ID: 34907378
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Lanthanum carbonate to control plasma and urinary oxalate level in type 1 primary hyperoxaluria?
    Pozdzik A; David C; Vekeman J; Tielens F; Daudon M
    IJU Case Rep; 2021 Jul; 4(4):235-238. PubMed ID: 34258537
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The Struggling Odyssey of Infantile Primary Hyperoxaluria.
    Guillaume A; Chiodini B; Adams B; Dahan K; Deschênes G; Ismaili K
    Front Pediatr; 2021; 9():615183. PubMed ID: 33959570
    [No Abstract]   [Full Text] [Related]  

  • 85. Microbial genetic and transcriptional contributions to oxalate degradation by the gut microbiota in health and disease.
    Liu M; Devlin JC; Hu J; Volkova A; Battaglia TW; Ho M; Asplin JR; Byrd A; Loke P; Li H; Ruggles KV; Tsirigos A; Blaser MJ; Nazzal L
    Elife; 2021 Mar; 10():. PubMed ID: 33769280
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Plasma oxalate and eGFR are correlated in primary hyperoxaluria patients with maintained kidney function-data from three placebo-controlled studies.
    Milliner DS; Cochat P; Hulton SA; Harambat J; Banos A; Dehmel B; Lindner E
    Pediatr Nephrol; 2021 Jul; 36(7):1785-1793. PubMed ID: 33515281
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Characteristics of the genotype and phenotype in Chinese primary hyperoxaluria type 1 populations.
    Zhao F; Li J; Tang L; Li C; Wang W; Ning C
    Urolithiasis; 2021 Feb; 49(1):17-25. PubMed ID: 32556641
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Stiripentol fails to lower plasma oxalate in a dialysis-dependent PH1 patient.
    Kempf C; Pfau A; Holle J; Müller-Schlüter K; Bufler P; Knauf F; Müller D
    Pediatr Nephrol; 2020 Sep; 35(9):1787-1789. PubMed ID: 32418144
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Inhibitors of Calcium Oxalate Crystallization for the Treatment of Oxalate Nephropathies.
    Kletzmayr A; Mulay SR; Motrapu M; Luo Z; Anders HJ; Ivarsson ME; Leroux JC
    Adv Sci (Weinh); 2020 Apr; 7(8):1903337. PubMed ID: 32328427
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Subclinical myocardial disease in patients with primary hyperoxaluria and preserved left ventricular ejection fraction: a two-dimensional speckle-tracking imaging study.
    Lagies R; Udink Ten Cate FEA; Feldkötter M; Beck BB; Sreeram N; Hoppe B; Herberg U
    Pediatr Nephrol; 2019 Dec; 34(12):2591-2600. PubMed ID: 31440827
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Biochemical properties and oxalate-degrading activity of oxalate decarboxylase from bacillus subtilis at neutral pH.
    Conter C; Oppici E; Dindo M; Rossi L; Magnani M; Cellini B
    IUBMB Life; 2019 Jul; 71(7):917-927. PubMed ID: 30806021
    [TBL] [Abstract][Full Text] [Related]  

  • 92. CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I.
    Zabaleta N; Barberia M; Martin-Higueras C; Zapata-Linares N; Betancor I; Rodriguez S; Martinez-Turrillas R; Torella L; Vales A; Olagüe C; Vilas-Zornoza A; Castro-Labrador L; Lara-Astiaso D; Prosper F; Salido E; Gonzalez-Aseguinolaza G; Rodriguez-Madoz JR
    Nat Commun; 2018 Dec; 9(1):5454. PubMed ID: 30575740
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Molecular basis of primary hyperoxaluria: clues to innovative treatments.
    Dindo M; Conter C; Oppici E; Ceccarelli V; Marinucci L; Cellini B
    Urolithiasis; 2019 Feb; 47(1):67-78. PubMed ID: 30430197
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Updated Genetic Testing of Primary Hyperoxaluria Type 1 in a Chinese Population: Results from a Single Center Study and a Systematic Review.
    Du DF; Li QQ; Chen C; Shi SM; Zhao YY; Jiang JP; Wang DW; Guo H; Zhang WJ; Chen ZS
    Curr Med Sci; 2018 Oct; 38(5):749-757. PubMed ID: 30341509
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Skin microvascular dysfunction as an early cardiovascular marker in primary hyperoxaluria type I.
    Bruel A; Bacchetta J; Ginhoux T; Rodier-Bonifas C; Sellier-Leclerc AL; Fromy B; Cochat P; Sigaudo-Roussel D; Dubourg L
    Pediatr Nephrol; 2019 Feb; 34(2):319-327. PubMed ID: 30276532
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.
    Hoppe B; Niaudet P; Salomon R; Harambat J; Hulton SA; Van't Hoff W; Moochhala SH; Deschênes G; Lindner E; Sjögren A; Cochat P
    Pediatr Nephrol; 2017 May; 32(5):781-790. PubMed ID: 27924398
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Primary hyperoxaluria: spectrum of clinical and imaging findings.
    Strauss SB; Waltuch T; Bivin W; Kaskel F; Levin TL
    Pediatr Radiol; 2017 Jan; 47(1):96-103. PubMed ID: 27844104
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Anaesthesia and intensive care for simultaneous liver-kidney transplantation: A single-centre experience with 12 recipients.
    Rajakumar A; Gupta S; Malleeswaran S; Varghese J; Kaliamoorthy I; Rela M
    Indian J Anaesth; 2016 Jul; 60(7):476-83. PubMed ID: 27512163
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Updated genetic testing of Italian patients referred with a clinical diagnosis of primary hyperoxaluria.
    Pelle A; Cuccurullo A; Mancini C; Sebastiano R; Stallone G; Negrisolo S; Benetti E; Peruzzi L; Petrarulo M; De Marchi M; Marangella M; Amoroso A; Giachino D; Mandrile G
    J Nephrol; 2017 Apr; 30(2):219-225. PubMed ID: 26946417
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Recurrence of crystalline nephropathy after kidney transplantation in APRT deficiency and primary hyperoxaluria.
    Bollée G; Cochat P; Daudon M
    Can J Kidney Health Dis; 2015; 2():31. PubMed ID: 26380104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.